Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
Submitted by
admin
on August 3, 2018 - 11:04am
Source:
CP Wire
News Tags:
Summit Therapeutics
C. difficile
microbiome ridinilazole
Headline:
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
snippet:
Ridinilazole treatment resulted in a 59% reduction in recurrence compared to vancomycin
C. difficile
causes approximately 500,000 infections and 29,000 deaths in the US annually
There are at least 12 products in development that target the microbiome in treating
C. difficile
Do Not Allow Advertisers to Use My Personal information
